sALT629
sALT629 is an orally active antitubercular agent with potent intramacrophage activity (EC50 = 1.5 μM). sALT629 shows broad-spectrum anti-Mycobacterium tuberculosis (Mtb) activities across four carbon sources, equipotent efficacy against drug-resistant Mtb, and activity against both slow-replicating and nonreplicating Mtb. sALT629 exhibits synergistic activity when combined with oxazolidinone drugs, such as Linezolid (HY-10394) and Sutezolid (HY-10392). sALT629 can be used for the research of tuberculosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 484026-63-3
- Formel: C13H17N5O2
- Molecular Weight:275.31
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
sALT629 (0.96-12.5 μM) exhibits inhibitory activity against Mtb cultured on four carbon sources (acetate, butyrate, cholesterol, glucose), with an EC50 of 1.5 μM against intramacrophage Mtb, an MIC of 0.8-1.7 μM against multidrug-resistant (MDR), extensively drug-resistant (XDR), and single-drug-resistant Mtb strains, and activity against slow-replicating and nonreplicating Mtb[1].
sALT629 (1.7-13.6 μM; 7 days) shows dose-dependent bactericidal activity against Mtb in 7H12 cholesterol media[1].
sALT629 (20 μM; 7 days) reduces CFU by approximately 1.5-log in the Hu-Coates 100-day dormancy model and by 0.5-log in Loebel's nutritionally deprived model[1].
sALT629 (>40 μM) shows no significant cytotoxicity against HEK293T and HepG2 cells, with a SI greater than 23[1].
sALT629 exhibits synergistic activity when combined with oxazolidinone drugs (Linezolid (HY-10394), Sutezolid (HY-10392)) with an FIC of 0.5, additive effects with drugs such as TBD11, TBA-7371 (HY-19750), and Q203 (HY-101040) (FIC=0.63-1.0), and no significant interaction with Isoniazid (HY-B0329) and other agents (FIC>1.0)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | Note | Cmax | Tmax | T1/2 | MRT0-last | AUC0-last | F |
|---|---|---|---|---|---|---|---|---|---|
| Mice | 20 mg/kg | p.o. | 文献审核 | 5,610 ng/mL | 0.83 h | 2.96 h | 2.85 h | 17,551 ng·h/mL | 55.1 % |
sALT629 (100 mg/kg BID, or 200 mg/kg QD, p.o., for 4 consecutive days) shows plasma concentrations remaining above EC50 for over 24 hours, and lung tissue exposure exceeds EC50[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 484026-63-3
-
Molecular Weight 275.31
-
Formel C13H17N5O2
-
SMILES
O=C(CN1N=NC(C2=CC=C(C=C2)OCC(C)C)=N1)N
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
sALT629 Related Classifications
HY-179649 Related Classifications
Powered by Bioz